Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Schrodinger, Inc.

NASDAQ: SDGR · Life Sciences · 5 alerts · CIK 1490978

Share price
$27.36Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Schrodinger, Inc. filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Schrodinger Q3 2026 Results: Net Loss of $37.7M, Loss Widens

Schrodinger, Inc. reported its third quarter 2026 results, highlighting a history of operating losses and expectations for continued losses as it invests in its computational platform and proprietary drug discovery programs. The company is focused on leveraging its agentic AI co-scientist and strategic collaborations, such as with Novartis, to drive software growth and clinical advancement.

Key figure
Net loss $37.7M
4:08 PM ET 8-K
Financial Results

Schrodinger Financial Results

Schrodinger reported Q3 2026 financial results with total revenue of $64.5 million, a 19% increase year-over-year, driven by 17% growth in Annual Contract Value (ACV). The company raised its full-year 2026 guidance for both ACV and drug discovery revenue following strong software performance and a milestone payment from Structure Therapeutics.

Term
Q3 2026

“We are very pleased with our third quarter performance, delivering 17% ACV growth, $24 million of drug discovery revenue, and raising our full-year ACV and drug discovery revenue outlook. Our strong performance highlights the power of our industry-leading platform and also our business model in which our software and drug discovery businesses reinforce each other.”

Ramy Farid, Ph.D., chief executive officer of Schrödinger

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.